Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity

Journal of Controlled Release

Volumn 129, Issue 1, 2008, Pages 26-32

  Kojima, Naoya ^a   Biao, Le ^a   Nakayama, Tomoko ^a   Ishii, Mariko ^a   Ikehara, Yuzuru ^b   Tsujimura, Kunio ^c  

^a TOKAI UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antigen delivery; Cancer immunotherapy; Cytotoxic T cells; Oligomannose coated liposome; Vaccine

Indexed keywords

ANTIGENS; CYTOTOXICITY; GROWTH KINETICS; IMMUNOLOGY; ONCOLOGY; TUMORS; VACCINES;

ANTIGEN DELIVERY; CANCER IMMUNOTHERAPY; CYTOTOXIC ACTIVITY; OLIGOMANNOSE COATED LIPOSOMES; THERAPEUTIC EFFICACY;

LIPOSOMES;

DRUG VEHICLE; IMMUNOLOGICAL ADJUVANT; LIPOSOME; MANNOSE; OLIGOMANNOSE COATED LIPOSOME; OLIGOSACCHARIDE; OVALBUMIN; TUMOR ANTIGEN; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL LYSATE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYMOMA; TUMOR CELL LINE; TUMOR IMMUNITY; TUMOR REJECTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; CANCER VACCINES; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; INJECTIONS, SUBCUTANEOUS; LIPIDS; LIPOSOMES; LYMPH NODES; MICE; MICE, INBRED C57BL; OVALBUMIN; TECHNOLOGY, PHARMACEUTICAL; THYMOMA; THYMUS NEOPLASMS; TIME FACTORS; TRISACCHARIDES;

EID: 44649161802     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.03.023     Document Type: Article

References (30)

1. Dziarski R., Wang Q., Miyake K., Kirschning C.J., and Gupta D. MD-2 enables Toll-like receptor 2 (TLR2)-mediated responses to lipopolysaccharide and enhances TLR2-mediated responses to Gram-positive and Gram-negative bacteria and their cell wall components. J. Immunol. 166 3 (2001) 1938-1944
2. Matsui K., Motohashi R., and Nishikawa A. Cell wall components of Staphylococcus aureus induce interleukin-5 production in patients with atopic dermatitis. J. Interferon Cytokine Res. 20 3 (2000) 321-324
3. Dao D.N., Kremer L., Guerardel Y., Molano A., Jacobs Jr. W.R., Porcelli S.A., and Briken V. Mycobacterium tuberculosis lipomannan induces apoptosis and interleukin-12 production in macrophages. Infect. Immun. 72 4 (2004) 2067-2074
4. Zhou F., and Huang L. Monophosphoryl lipid A enhances specific CTL induction by a soluble protein antigen entrapped in liposomes. Vaccine 11 11 (1993) 1139-1144
5. Takeuchi O., Sato S., Horiuchi T., Hoshino K., Takeda K., Dong Z., Modlin R.L., and Akira S. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol. 169 1 (2002) 10-14
6. Kawai T., and Akira S. Pathogen recognition with Toll-like receptors. Curr. Opin. Immunol. 17 4 (2005) 338-344
7. Tacken P.J., Torensma R., and Figdor C.G. Targeting antigens to dendritic cells in vivo. Immunobiology 211 6-8 (2006) 599-608
8. Altin J.G., and Parish C.R. Liposomal vaccines-targeting the delivery of antigen. Methods 40 1 (2006) 39-52
9. Altin J.G., van Broekhoven C.L., and Parish C.R. Targeting dendritic cells with antigen-containing liposomes: antitumour immunity. Expert Opin. Biol. Ther. 4 11 (2004) 1735-1747
10. Park J.W., Kirpotin B.D., Hong K., Shalaby R., Shao Y., Nielsen U.B., Marks J.D., Papahadjopolous D., and Benz C.C. Tumor targeting using anti-her2 immunoliposomes. J. Control. Release 74 1-3 (2001) 95-113
11. Gieseler R.K., Marquitan G., Hahn M.J., Perdon L.A., Driessen W.H., Sullivan S.M., and Scolaro M.J. DC-SIGN-specific liposomal targeting and selective intracellular compound delivery to human myeloid dendritic cells: implications for HIV disease. Scand. J. Immunol. 59 5 (2004) 415-424
12. van Broekhoven C.L., Parish C.R., Demangel C., Britton W.J., and Altin J.G. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res. 64 12 (2004) 4357-4365
13. Kawamura K., Kadowaki N., Suzuki R., Udagawa S., Kasaoka S., Utoguchi N., Kitawaki T., Sugimoto N., Okada N., Maruyama K., and Uchiyama T. Dendritic cells that endocytosed antigen-containing IgG-liposomes elicit effective antitumor immunity. J. Immunother. (1997) 29 2 (2006) 165-174
14. White K.L., Rades T., Furneaux R.H., Tyler P.C., and Hook S. Mannosylated liposomes as antigen delivery vehicles for targeting to dendritic cells. J. Pharm. Pharmacol. 58 6 (2006) 729-737
15. Copland M.J., Baird M.A., Rades T., McKenzie J.L., Becker B., Reck F., Tyler P.C., and Davies N.M. Liposomal delivery of antigen to human dendritic cells. Vaccine 21 9-10 (2003) 883-890
16. Ikehara Y., Niwa T., Biao L., Ikehara S., Ohashi N., Kobayashi T., Shimizu Y., Kojima N., and Nakanishi H. A carbohydrate recognition based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. Cancer Res. 66 17 (2006) 8740-8748
17. Ikehara Y., and Kojima N. Development of a novel oligomannose-coated liposome-based anticancer drug delivery system for intraperitoneal cancer. Curr. Opin. Mol. Ther. 9 1 (2007) 53-61
18. Takagi H., Furuya N., and Kojima N. Preferential production of IL-12 by peritoneal macrophages activated by liposomes prepared from neoglycolipids containing oligomannose residues. Cytokine 40 3 (2007) 241-250
19. Ikehara Y., Shiuchi N., Kabata-Ikehara S., Nakanishi H., Yokoyama N., Takagi H., Nagata T., Koide Y., Kuzushima K., Takahashi T., Tsujimura K., and Kojima N. Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal macrophage. Cancer Lett. 260 1-2 (2008) 137-145
20. Shimizu Y., Yamakami K., Gomi T., Nakata M., Asanuma H., Tadakuma T., and Kojima N. Protection against Leishmania major infection by oligomannose-coated liposomes. Bioorg. Med. Chem. 11 7 (2003) 1191-1195
21. Shimizu Y., Takagi H., Nakayama T., Yamakami K., Tadakuma T., Yokoyama N., and Kojima N. Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishmanial antigen induces antigen-specific T-helper type 1 immune response in Balb/c mice through uptake by peritoneal macrophages. Parasite Immunol. 29 5 (2007) 229-239
22. Moore M.W., Carbone F.R., and Bevan M.J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54 6 (1988) 777-785
23. Reddy S.T., Swart M.A., and Hubbell J.A. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol. 27 12 (2006) 573-579
24. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M.L., Knutson K.L., Chen L., and Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 9 (2004) 942-949
25. Baxevanis C.N., Sotiriadou N.N., Gritzapis A.D., Sotiropoulou P.A., Perez S.A., Cacoullos N.T., and Papamichail M. Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol. Immunother. 55 1 (2006) 85-95
26. Chang A.E., Redman B.G., Whitfield J.R., Nickoloff B.J., Braun T.M., Lee P.P., Geiger J.D., and Mule J.J. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res. 8 4 (2002) 1021-1032
27. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20 (2002) 709-760
28. Jahrsdorfer B., and Weiner G.J. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy. Curr. Opin. Investig. Drugs 4 6 (2003) 686-690
29. van Duin D., Medzhitov R., and Shaw A.C. Triggering TLR signaling in vaccination. Trends Immunol. 27 1 (2006) 49-55
30. Heikenwalder M., Polymenidou M., Junt T., Sigurdson C., Wagner H., Akira S., Zinkernagel R., and Aguzzi A. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. 10 2 (2004) 187-192